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Abstract: Despite the success of arsenic trioxide (ATO) in treating haematological malignancies,
its potential to treat solid tumours has not been fully exploited, owing to its dose-limiting toxicity
and poor pharmacokinetics. In order to overcome this hurdle, liposomal encapsulation of the drug
with different surface charges (neutral, negative, and positive) and sizes (100, 200 and 400 nm)
were synthesised and tested on human papilloma virus (HPV)-positive HeLa and HPV-negative
HT-3 cervical cancer cell lines. Two epithelial cell lines—human keratinocytes (HK) and human
colon cells (CRL-1790)—were used as controls. The synthesised liposomes were tested for their
physico-chemical characteristics, drug loading efficiency, and toxicity on the studied cell lines. Neutral
liposomes of 100 nm in size were the chosen formulation for delivering ATO into the studied cells,
as they showed the least intrinsic cytotoxicity and the highest loading efficiency. The findings
demonstrated that the optimised formulation of liposomes was an effective drug delivery method for
HPV-infected cervical cancer cells. Furthermore, the toxicity vs. uptake ratio was highest for HeLa
cells, while a reduced or minimal toxic effect was observed for non-HPV-infected cervical cancer
cells and control cells. These findings may provide a promising therapeutic strategy for effectively
managing cervical cancers.
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1. Introduction
Cervical cancer is responsible for 14% of all gynaecological cancers in women, and is linked to
high-risk human papilloma virus (HPV) infections [1–3]. Among all of the high-risk HPV subtypes,
HPV-16 and HPV-18 account for 70% of all cervical cancers [4,5]. Invasive cervical cancer management
depends on the stage of the cancer, histological type, and the age of the patient. The most common
treatment is surgery and/or chemoradiotherapy, which usually results in severe side effects [6,7].
Therefore, alternative treatment options that provide better efficacy and specificity with fewer side
effects on the surrounding healthy tissues and cells are necessary. An anti-HPV agent that can be
taken up more specifically by HPV-infected cells is needed because of the crucial role of high-risk
HPV infections in the pathogenesis of cervical cancer. In addition, if a drug carrier can deliver the
drug to the cancer cells and release it slowly, a consistent flow of medication—which may enhance
the therapeutic effect of the delivered drug—could be maintained. Moreover, the toxic effects on
non-HPV-infected surrounding cells and tissues would be reduced.
Arsenic trioxide (ATO) was approved by the Food and Drug Administration (FDA) in 2000 as
a first-line treatment option for acute promyelocytic leukaemia (APL). It has also been found to be
effective for other haematological malignancies in vitro [8–11]. Although ATO has displayed some
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anti-cancer effects in vitro, poor pharmacokinetics and its dose-limiting toxicity have caused it to
not exhibit appreciable clinical success on human patients when its efficacy was tested for solid
tumours [11]. In order to overcome this difficulty and improve ATO’s anti-cancer properties for solid
tumours (specifically cervical cancer), a mechanism is needed for increasing the drug’s therapeutic
index by sparing the surrounding healthy tissue from arsenic toxicity. This could be achieved by
encapsulating the drug using nanotechnology.
Nanotechnology-based drug delivery systems can specifically target cancer cells while avoiding
their healthy neighbours and avoiding rapid clearance from the body, thereby considerably increasing
the therapeutic index of the drug [6,12]. Among the many nanocarriers that have been discovered to
date, the oldest and most commonly employed nanoparticles are liposomes [13–15]. Chen et al. (2006)
utilised the “remote loading phenomenon” to stably encapsulate ATO in liposomes. As arsenic tends
to combine with transition metal ions such as NiII, CoII, and PtII to form a precipitate, liposomes
were loaded with an acetate solution of Ni prior to the addition of ATO [16]. An efflux of protonated
acetic acid drove ATO to be efficiently loaded and stably encapsulated within the liposomes, with the
transition metal ion in the form of a solid crystalline precipitate [16].
Although they are an exciting and promising prospect, optimisation is required in order to
use liposomes as a desirable drug delivery vehicle. There are many physicochemical characteristics
that need to be considered, including size, surface charge, zeta potential, shape, membrane lipid
packing, steric stabilization, and polyethylene glycol (PEG) fluidity. These features influence the
pharmacokinetic properties of liposomes by controlling the clearance process, surface toxicity,
mononuclear phagocytic system (MPS) recognition, and enhanced permeability and retention effect
(EPR) [17,18]. Among these factors, size and surface charge are the two key characteristics of
nanoparticles that affect their EPR, immune clearance, and cellular adhesion and uptake [19].
While a few studies have investigated the effects of both the surface charge and size of liposomes
on cellular uptake, the results have been inconsistent [19–23]. Regarding surface charge, Nie et al. [19]
reported that positively-charged cationic liposomes were more readily taken up by cells—both in vitro
and in vivo—because of the interaction with the negatively-charged cell membrane. In contrast,
Miller et al. [20] found that a negative surface charge on liposomes increased endocytosis by some cell
types. An earlier study reported that liposome–cellular interaction depends not only on the liposomal
charge, but also on the lipid composition and—more importantly—the cell type [21]. Therefore, it is
crucial to optimise the liposomal construct in order to identify the best charge for the target cancer cell
line under investigation.
An optimum size for nanoparticles is also important, as the kidneys rapidly clear any nanoparticle
with a size below 10 nm, while those above 150 nm in size would face the risk of recognition and clearance
by the body’s immune system [22]. However, larger nanoparticles have been reported to benefit from
having higher encapsulation efficiencies, which increases drug delivery to the target tissue [23].
Based on the inconsistency of previous findings, the aim of this study was to identify the most
suitable liposomal formulation—with respect to size and charge—for delivering ATO into cervical
cancer cells, and thereby enhance the therapeutic potential of the delivered drug. The uptake and
anti-tumoural efficacy of ATO using the optimised liposomal formulation were examined using two cervical
cancer cell lines—namely HeLa (HPV-positive) and HT-3 (HPV-negative)—along with two cell lines as
controls—namely human epidermal keratinocytes (HK) and human colon epithelial cells (CRL-1790).
2. Results
2.1. Liposome Preparation and Characterization
The mean size and zeta potential of control liposomes were determined by dynamic light
scattering (DLS) on a Zetasizer-Nano ZS (Malvern Instruments, Malvern, UK). The DLS measurements
of the hydrodynamic sizes of the 100 nm, 200 nm, and 400 nm liposomes were 138.5 ± 1.22 nm,
187 ± 2.96 nm, and 243 ± 2.68 nm, respectively. All of the charged liposomes were extruded through
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a 100 nm filter. Positively-charged and neutral phosphatidylcholine (PC) liposomes had a similar
hydrodynamic size of 138.5 ± 1.22 nm and 143.9 ± 3.19 nm, respectively. However, the incorporation
of a negatively-charged lipid (DSPG: 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol), sodium
salt) slightly increased the particle size to 165.2 ± 3.26 nm. No significant differences were observed
between these three sizes. The polydispersity index of the investigated vesicles had values ranging
from 0.12 to 0.175, indicating a homogenous population of liposomes. Regarding the zeta potential, the
group of liposomes that exhibited a small negative surface charge, (−) 24.4 ± 0.46 mV was considered
neutral. Cationic liposomes possessed a positive charge, (+) 23.2 ± 0.44 mV, and negative liposomes
possessed a higher negative charge, (−) 36.4 ± 0.75 mV.
The liposomes were efficiently loaded with arsenic, which was co-encapsulated with the transition
metal ion, Ni. The phospholipids—encapsulated arsenic and nickel—in the liposomes were quantified
by inductively coupled plasma optical emission spectrometry (ICP-OES). The loading efficiencies
(phospholipids/encapsulated arsenic—As/P) of liposomes of different sizes and charges are presented in
Figure 1. The loading efficiency was highest for neutral liposomes of 100 nm in size at 24.2% As/P (±0.848).
Figure 1. Loading efficiency of synthesised liposomes by inductively coupled plasma optical
emission spectrometry (ICP-OES). Loading efficiency (% phospholipids/encapsulated arsenic—As/P)
of liposomes of (a) different sizes and (b) different charges. All of the different-sized liposomes
(100 nm, 200 nm, and 400 nm) have a neutral charge, whereas all of the different-charged liposomes
(neutral, positive, and negative) are 100 nm in size. Data are presented as mean ± standard deviations
(SD) of three replicate measurements of at least three independent experiments. An unpaired t test
(p > 0.05) was used to test for any significant difference in the loading efficiency of liposomes of three
sizes (ranging from 100 to 400 nm), and three charges (neutral, negative, and positive). No significant
difference was observed between the liposomes of different sizes, although neutral liposomes displayed
a significantly higher loading efficiency than the others (* p < 0.05).
In order to assess the effect of pH on the liposomal formulation (and hence determine the drug
leakage pattern that is initiated when encountering different pH), liposomes were dialysed in buffers
of pH 4, pH 7 and pH 10. The amounts of the drug that were retained in the liposomes were examined
after periods of 1, 2, 4, 6, and 24 h (Figure 2). At pH 4, approximately 40% of the drug was lost within
the first four hours. Among the different sizes, the smallest (100 nm) liposomes were found to be the
most stable at all pH values. With respect to charge, the negatively-charged liposomes displayed a
significant loss of stability when they were exposed to a higher pH in comparison with those with a
neutral or positive charge.
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Figure 2. Stability studies of different liposomal formulations under various pH conditions.
Arsenic trioxide (ATO) was encapsulated in liposomes of (a) different sizes and (b) different charges
after dialysing in buffers at pH 4, pH 7, and pH 10. Data are shown as mean ± SD of three independent
experiments; * p < 0.05, ** p < 0.01.
2.2. Analysing Cytotoxicity of Control Empty Liposomes with Different Sizes and Charges
Control empty liposomes of various formulations were synthesised and tested—using the
1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay—for their cytotoxicity towards HeLa
cells at 24, 48 and 72 h (Figure 3). The phospholipid concentrations of the liposomes were diluted at the
same dilution factor that was used for liposomal ATO. No significant difference in the cytotoxicity from
different-sized liposomes was observed at the relevant concentrations of liposomes. However, when
the surface charges were taken into consideration, the empty positively-charged liposomes displayed
significant toxicity over an incubation period of 48 h.
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Figure 3. The MTT assay used to test the cytotoxicity of various control liposomal formulations on
cervical cancer cells. The cellular toxicity that is induced by control (empty) liposomes of different
(a) sizes and (b) charges is represented following an incubation period of 24, 48 and 72 h with HeLa
cells. The positively-charged liposomes displayed noticeable toxicity at 48 h exposure and at the same
dilution factor that was used for diluting liposomal encapsulated ATO. Neutral liposomes were found
to show the least toxicity. Data are presented as mean ± SD of three replicate experiments; ** p < 0.01.
PC: phosphatidylcholine.
2.3. Cytotoxicity and Uptake of ATO-Encapsulated Liposomes in HPV-Positive and HPV-Negative Cervical
Cancer Cell Lines
After establishing that neutral liposomes of 100 nm in size were the most stable formulation,
possessed the highest encapsulation efficiency, and displayed the least intrinsic toxicity, this form
of liposome was chosen as the drug carrier for the remainder of the experiments. The response of
cervical cancer cell lines of differing HPV statuses (HPV-positive HeLa and HPV-negative HT-3) to the
treatment with ATO—delivered either in the free form or encapsulated in the chosen liposomes—was
investigated with regards to cytotoxicity (MTT assay), cellular uptake (inductively coupled plasma
mass spectrometry, ICP-MS), and induction of apoptotic response (flow cytometry).
The MTT results demonstrated that the cell survival rates after treatment in both cervical cancer
cell lines were similar for up to 72 h (Figure 4a). In addition, the cell survival rates were found
to be lower in cells that were exposed to free ATO as opposed to liposomal-encapsulated ATO.
This trend became more noticeable as the drug exposure time increased. Using flow cytometry to
measure apoptosis (Figure 4b), no statistically significant difference was found between the apoptotic
populations in HT-3 and HeLa cell lines after incubation with either free or encapsulated ATO for
up to 48 h treatment (Figure 4b). However, a clear trend of increased cell death induced by directly
exposing both of the cell lines to free ATO was observed. The IC50 results that were obtained from
the cytotoxicity assays are presented in Figure 4c. The results display similar values for both of the
treatments on HeLa and HT-3 cells after 48 h of incubation.
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Figure 4. The MTT assay and flow cytometry analysis to compare cellular toxicity and apoptosis
induction of varying treatments on HeLa and HT-3 cells. (a) Cell viability of HeLa and HT-3 cell lines
following incubation with liposomal encapsulated ATO (ATO lipo) and free ATO for 24, 48 and 72 h;
(b) Flow cytometry analysis of apoptotic populations that were treated with complete media as control,
empty liposomes, liposomal 5 µM ATO, or 5 µM free ATO on HeLa and HT-3 cell lines following
treatment for 24 and 48 h; (c) Calculated IC50 values for ATO lipo and free ATO treated HeLa and HT-3
cells after 24, 48, and 72 h. Data are presented as mean ± SD of three replicate experiments.
Despite a similar response to treatment with free and encapsulated ATO from both of the cell
lines with respect to toxicity and induction of apoptosis, the uptake of both free and liposomal arsenic
by the cell lines varied at different time points (as can be observed in Figure 5a). The uptake by HT-3
cells was found to be higher than the uptake by HeLa cells at 6 and 24 h. This trend reversed for the
free drug uptake at 48 h treatment, when HeLa cells were observed to have taken up significantly
more ATO. In Figure 5b, toxicity–uptake ratios for HeLa and HT-3 are shown to indicate the level of
toxicity that was induced in the cell lines per unit of arsenic taken up by the cells. Liposomal ATO was
observed to be more effective than the free drug in inducing toxicity per unit of arsenic uptake in both
cell lines. However, liposomal ATO treatment was more toxic to HeLa cells than to HT-3 cells.
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Figure 5. A comparative study of the arsenic uptake and toxic response of different drug formulations
on HeLa and HT-3 cells. (a) Comparison of the arsenic uptake by HeLa and HT-3 after 6, 24, and 48 h
of treatment—as determined by inductively coupled plasma mass spectrometry (ICP-MS). Free ATO
was taken up more than ATO lipo in both cell lines. However, the uptake was higher in HT-3 for all
treatments, except for the free ATO uptake after 48 h. (b) Ratios of toxicity vs. uptake of liposomal and
free ATO for the two cervical cancer cell lines after 24 h treatment. Data are displayed as mean ± SD
from at least three independent experiments; * p < 0.05, ** p < 0.01, and *** p < 0.001.
2.4. Selectivity of Liposomal Encapsulated ATO in Killing Cervical Cancer Cells
After establishing the efficacy of liposomal ATO in inducing toxicity per unit of arsenic uptake
in HPV-positive HeLa cells, we further investigated the effect of liposomal ATO on non-cancerous
cells by choosing two cell lines as controls, namely human keratinocytes (HK) and human colon cells
(CRL-1790) (Figure 6a,b). Among the three cell lines investigated, the uptake of liposomal arsenic
was highest in HK cells, with a lower uptake by HeLa and CRL-1790 cells. In contrast, the highest
uptake of free ATO was by HeLa cells (Figure 6a). However, when cytotoxicity was investigated, cell
survival was insignificantly affected in CRL-1790 and HK cell lines (Figure 6b). The ratio of toxicity to
the amount of arsenic taken up by the cells after incubation with liposomal encapsulated ATO and
free ATO for 24 h is presented in Figure 6c. Liposomal ATO resulted in a higher cell death rate per
unit uptake of arsenic than free ATO for HeLa cells, while a minimal toxic effect was observed in the
control cells. The IC50 values for the liposomal ATO treatment were calculated, and were higher for
the control cell lines than for HeLa cell lines (Figure 6d).
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Figure 6. Arsenic uptake and toxic response in the control cells and HeLa cells. (a) A comparative study of
arsenic concentration per cell in CRL-1790, human epidermal keratinocyte (HK), and HeLa—as determined
via ICP-MS after 24 h of treatment with media, control liposomes, ATO lipo, and free ATO; (b) Cell survival
following the exposure of cervical cancer and control cell lines to ATO lipo for 24 h—assessed using the
MTT assay; (c) Toxicity–uptake ratio of ATO lipo and free ATO in HeLa cells compared to control cell
lines, after treatment for 24 h. ATO lipo is effective in generating toxicity in HeLa cells, while having a
non-toxic effect on the normal cells; (d) The IC50 values for three cell lines following 24 h of ATO liposomal
treatment. Data are displayed as mean ± SD from three replicates; * p < 0.05, ** p < 0.01.
3. Discussion
Since the recognition of the potential of ATO as a broad spectrum anti-cancer drug, it is being
increasingly explored for the treatment of various cancer types [11]. However, the systemic toxicities
that are associated with this drug when treating solid cancers impedes its therapeutic use in clinical
applications. We have previously shown that a low concentration of ATO (≤2 µM) is capable of
selectively inducing cellular apoptosis and increasing p53 expression in HPV-positive cervical cancer
cells in vitro [24]. However, increasing the ATO dosage to 5 µM resulted in most of the cells being killed
because of drug-induced toxicity, irrespective of their HPV status. In order to reduce ATO’s toxicity
and raise its therapeutic index, liposomal encapsulated ATO at 5 µM was used to treat cervical cancer
cells [25]. The results from our previous study indicated that, although liposomal ATO was less readily
taken up by cells than free ATO [26], the delivered ATO was able to reduce the oncogene E6 expression
while exhibiting reduced toxicity [25]. Since the size and surface charge of liposomes play important
roles in drug stability and sustained release, an optimised liposome formulation with appropriate
physical features would be essential for further improving the drug loading efficiency and boosting
the killing effects for cancer cells. Therefore, the aim of this work was to optimise the liposomal
design—with respect to size and charge—for use as drug delivery vehicles to specifically target
HPV-positive cervical cancer cells in vitro. Liposomes of different sizes (100 nm, 200 nm, and 400 nm)
and different charges (neutral, positive, and negative) were synthesised, with ATO co-encapsulated
with a transition metal ion (Ni2+) in a stable, precipitate form.
The size measurement analysis indicated a disparity between the actual and expected sizes of the
formed liposomes. The 200 nm liposomes were closest to the expected size, with the 100 nm liposomes
being slightly larger and the 400 nm liposomes being smaller. This could be caused by the choice of
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filter extruders (discontinuous syringe filtration vs. continuous high-pressure devices), the inaccuracy
of the actual pore diameter of the commercial filter, or the particle size analysis technique that was
employed [27]. However, as these liposomes still displayed an expected incremental size range, it was
decided to proceed with the planned analysis.
Circulating liposomes with stability in the retention of drugs is a desirable feature in order to
ensure that a sufficient amount of the drug reaches the target tissue. The pH stability studies were
carried out under three pH conditions (pH 4, pH 7 and pH 10). Among the studied sizes, 100 nm
liposomes were the most stable at all three pH values. Negative liposomes displayed instability at
higher pH, most likely owing to the changes in lipid orientation in the alkaline conditions leading to
liposome disintegration [28].
The results from the drug loading efficiency studies among different formulations indicated that
100 nm neutral liposomes had the highest drug encapsulation. Since the success of nanoparticles as
drug carriers relies on them being inherently non-toxic, we further tested whether these liposomes
displayed any intrinsic toxicity towards the cells. This was tested by incubating their empty
counterparts with HeLa cells for 24, 48 and 72 h. The dilutions of liposomes that were tested for
toxicity studies were the same as the dilutions that were used for preparing liposomal encapsulated
ATO samples. Size did not have any significant effect on toxicity in the range that was tested (Figure 3a).
However, among the charged liposomes, positively-charged liposomes began to display toxicity to
HeLa cells after 48 h of incubation, killing almost 20% of cells at the dilutions that were employed for
the treatment (Figure 3b). One possible reason suggested for the high toxicity of cationic lipids is their
translocation to the cell membrane, which eventually results in its destabilisation [29]. This finding
excludes positively-charged liposomes from being employed as drug carriers for ATO delivery to
cervical cancer cells, even though a higher uptake by cells was previously observed with this type of
liposome [19]. Moreover, negatively-charged liposomes were demonstrated to be unstable at a higher
pH. Considering the above reasons, 100 nm, neutral liposomes were chosen as the carrier for ATO
delivery and were used for further in vitro analysis.
Further investigations on cytotoxicity and apoptosis induced by treatments with liposomal ATO
and the free drug indicated a trend of toxicity increasing with drug exposure time in both of the
cervical cancer cell lines that were tested (Figure 4a,b). An ICP-MS examination of the amount of
ATO that was taken up by cells indicated that, using both delivery methods, HT-3 cells took up more
arsenic than HeLa cells (Figure 5a). The ratio of toxicity to uptake indicates that liposomal ATO was
71 times more toxic to HeLa cells than to HT-3 cells per unit of arsenic. In contrast, free ATO was more
efficient in inducing a toxic response per unit of arsenic in HT-3 cells, which demonstrates the selective
nature of liposomal encapsulated ATO for HPV-positive HeLa cells. This finding further supports
the suitability of the optimised formulation of liposomes as the desired nanocarrier for introducing
arsenic to HPV-positive cell lines. A significantly higher uptake of free ATO by HT-3 cells, compared
to HeLa cells, was observed after 6 and 24 h of drug exposure. However, the arsenic concentration
in HT-3 cells was then observed to have fallen after 48 h of incubation. This may be attributed to the
activation of cellular efflux mechanisms in HT-3 cells. This trend was not observed in HeLa cells, with
ATO concentrations continuing to increase at 48 h. It could be postulated that this was related to the
presence of HPV within the cell. The mechanism behind this warrants further investigation.
One of the main aims of employing nanotechnology in pharmaceutics is to deliver the drug
specifically to the cancer cells while sparing the normal cells. There has been a lack of literature
reporting on studies involving non-cancerous cell lines while investigating liposomal ATO efficacy
in vitro. Hence, after establishing the effectiveness of the liposomal construct for HPV-positive cervical
cancer cells, we decided to investigate the toxicity and uptake response profile of non-cancerous
control cells to liposomal treatment. Two control cell lines were chosen for this study, namely human
keratinocytes (HK) and human colon (CRL-1790) cells. The uptake of liposomal arsenic by HK cells
was found to be higher than in the other cell lines (Figure 6a). The second control cell line, CRL-1790,
displayed lower intracellular arsenic concentrations than HeLa cells after incubation with liposomal
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ATO (Figure 6a). However, after 24 h of treatment with liposomal encapsulated ATO, results showed
that the non-cancerous cell lines were the least affected by the treatment, with cell survival rates
close to 95% at the same length of incubation and the same dose of the treatment (Figure 6b). This is
independent of the amount of ATO uptake by the cells. This finding suggests that liposomal-delivered
ATO could be a promising candidate for targeting cervical cancer cells, because it demonstrated less
toxicity to the non-cancerous cells—even at a much higher concentration. It may be the case that when
liposomal-encapsulated ATO reaches the cells, it results in bio-physical changes in the cell membrane
that may in turn affect the cellular transport systems. Different types of cells may react to these changes
in different ways. However, HeLa cells appear to be more vulnerable to this drug treatment, which
could be relevant to HPV.
The toxicity–uptake ratio indicates the toxicity induced per unit of liposomal arsenic uptake,
and is an effective means of comparing the efficacy of a treatment on different cell populations. For an
ideal treatment, the toxicity–uptake ratio would be low for normal cells and high for the target cancer
cell population. Our results indicated that this ratio was indeed lowest for the control cell populations
and highest for HeLa cells, indicating that liposomal-encapsulated ATO is a promising treatment for
HPV-positive cervical cancers.
In conclusion, our current research confirms the potential of delivering ATO into HPV-infected
cervical cancer cells using a liposomal drug carrier that is optimised with respect to drug loading
efficiency, stability, cellular uptake, and apoptotic response by cancer cells. This nanodelivery method
exhibits a better potential efficacy in the treatment of cervical cancers than using free-form ATO
treatment, in that it demonstrates a higher ratio of drug toxicity to ATO uptake in the cells. Future work
is warranted for evaluating whether the levels of high-risk HPV oncogenes in cervical cancer cells are
reduced following this treatment and for investigating the mechanisms behind the changes. Should this
prove to be the case, liposomal-encapsulated ATO may provide a novel effective therapeutic option in
managing cervical cancers and possibly other HPV-associated cancers.
4. Materials and Methods
4.1. Materials
RPMI1640, L-glutamine, penicillin-streptomycin, and foetal bovine serum (FBS) were
purchased from Invitrogen Life Technologies (Paisley, UK). EpiLife® Medium, with 60 µM calcium;
Human Keratinocyte Growth Supplement (HKGS); and nitric acid were obtained from Fisher Scientific
(Loughborough, UK). Soy phosphatidylcholine (PC) and 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol)
(sodium salt) (DSPG) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Methoxypolyethyleneglycol-distearoyl-phosphatidylethanolamine (DSPE-PEG2000; with mPEG MW2000Da)
was obtained from Genzyme (Suffolk, UK). Cholesterol (Chol), phosphate-buffered saline (PBS), Triton-100,
ATO, nickel acetate, didodecyldimethylammonium bromide (DDAB), thiazolyl blue tetrazolium bromide
powder (MTT), and dialysis tubing were purchased from Sigma (Welwyn Garden City, UK). DMEM
Media—GlutaMAX™, methanol, and dichloromethane were obtained from Thermofisher (Paisley, UK).
An Annexin V FITC/PI apoptosis detection kit was purchased from Abcam (Cambridge, UK).
4.2. Liposome Preparation and Characterization
Liposomes of different sizes were composed of soy PC, cholesterol, and DSPE-PEG2000 at a molar
ratio of 54:45:1 mol %. Liposomes were prepared as has been described elsewhere [30]. Briefly, the lipids
were dissolved in 1:2 methanol:dichloromethane (v/v) at room temperature. The lipid mixtures
were deposited on the side wall of the rotary glass vial by removing the solvent using nitrogen.
The dried lipid films were hydrated in 730 mM nickel acetate (Ni(OAc)2) aqueous solution for 1 h
with gentle rotation. This process led to the spontaneous formation of multi-lamellar PEGylated
liposomes. The liposome suspension was subsequently subjected to 10 freeze–thaw cycles (freezing in
liquid nitrogen for 3 min and thawing in a 37 ◦C water bath for 3 min), followed by downsizing by
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passing through 0.1, 0.2 and 0.4 µm Anotop filters (Whatman, Cambridge, UK) to form different-sized
liposomes. Extruded liposomes were dialysed against a 10 mM sodium phosphate buffer at pH 7 to
get rid of unencapsulated Ni(OAc)2. The nickel acetate-encapsulated liposomes were then incubated
with 20 mM ATO solution at room temperature for 5 h. Following the removal of unencapsulated
ATO by dialysis, the concentrations of phospholipids (P), encapsulated arsenic (As), and nickel (Ni)
in the liposomes were determined by an inductively coupled plasma optical emission spectrometer
(ICP-OES; Thermo-Scientific iCap 6500 ICP, Stafford, UK). The molar ratios of As/P were calculated
and used to determine the loading efficiency. Liposomal stability was determined by checking the
As/P ratio over a period of 4 weeks, during which liposomes were stored at 4 ◦C in buffers of
pH 7.4. Drug leakage at different pH was studied by dialysing liposomes in buffers of pH 4, pH 7
and pH 10 and assessing their loading efficiency at a period of 1, 2, 4, 6 and 24 h by measuring the
As/P ratio of the samples by ICP-OES. The mean liposome sizes and zeta potential (a measure of
the charges that are carried by particles that are suspended in liquid) were determined by dynamic
light scattering on a Zetasizer-Nano ZS (Malvern Instruments, Malvern, UK). Liposomes of different
charges were prepared as described above—with the exception of positive liposome composition,
which was PC/Chol/DSPE-PEG2000/DDAB at a molar ratio of 50/33/1/16, and negative liposome
composition, which was PC/Chol/DSPE-PEG2000/DSPG at molar ratio of 50/33/1/16. The positive
and negative liposomes were extruded with 0.1 µm Anotop filters. The loading efficiency, stability,
drug leakage, size, and zeta potential of these liposomes were investigated as outlined above.
4.3. Cell Culture
Two cervical cancer cell lines, HeLa and HT-3 (ATCC, Manassas, VA, USA), and two
control cell lines, human epidermal keratinocytes HK (Fisher Scientific, Loughborough, UK) and
human colon epithelial cells CRL-1790 (ATCC, Manassas, VA, USA), were employed in this study.
HeLa cells (HPV-18-positive) and HT-3 (HPV-negative) were cultured in RPMI 1640 complete media,
and CRL-1790 were grown in DMEM media, containing 10% foetal calf serum FCS, 100 U/mL of
penicillin, and 100 mg/mL streptomycin in 75 cm2 flasks. HK cells were cultured in Epilife media,
which was supplemented with HKGS. The cells were grown in a humidified incubator containing 5%
CO2 and 95% air at 37 ◦C until they reached 90% confluence. The following experiments were then set
up for further studies concerning liposomal ATO exposure at different time intervals: cellular toxicity
via MTT assay, flow cytometry analysis for cell apoptosis, and quantification of cellular arsenic uptake
by inductively coupled plasma mass spectrometry (ICP-MS).
4.4. Cellular Toxicity via MTT Assay
The cytotoxicity of various liposomal formulations of ATO was determined by the MTT assay,
as described previously [31]. Briefly, the experiment was set up in a 96-well plate, where the toxicity
of control empty liposomes was investigated by taking an initial starting amount containing 0.5 mM
of phospholipid concentration and diluting it further in a 1:10 ratio to a further six wells. The ATO
encapsulating liposomes contained 30 µM of ATO in the initial sample, which was further diluted to a
1:6 ratio down to six wells. The wells were seeded with HeLa, HT-3, CRL-1790, and HK at 0.6 million
cells per mL and incubated at 37 ◦C in the humidified incubation chamber for 24 h, 48 h and 72 h.
After each time interval, the spent media was removed carefully and 50 µL of MTT solution was added
into each well. After 30 min incubation at 37 ◦C, with 95% O2 and 5% CO2, MTT reagent was removed
carefully from each well, 100 µL propanol was added to dissolve the crystals, and it was incubated at
37 ◦C for at least 30 min. The absorbance of this coloured solution was quantified by measuring at
a wavelength of 570 nm, using a BMG LabTech FLUOstar Omega Plate Reader (Bucks, UK).
4.5. Cell Apoptosis by Flow Cytometry
The cells from the four different cell lines were seeded at 5× 105/mL in six-well culture plates and
grown overnight. Neutral liposomes of 100 nm in size were employed for this experiment. After 24 h of
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treatment (media only, liposomal ATO at a dilution having 5 µM ATO encapsulated, empty liposomes at
the same dilution as liposomal ATO, 5 µM free ATO), the cells were trypsinised, washed twice with PBS,
and then collected into 15 mL centrifuge tubes for further staining. The cells were re-suspended in an
Annexin-V binding buffer, before incubating them with fluorescein isothiocyanate (FITC)-conjugated
Annexin-V and propidium iodide (PI) according to the protocol (Abcam, Cambridge, UK). All of the
samples were analysed within 1 h of PI staining using BD FACSCalibur (BD, Oxford, UK).
4.6. Quantitative Analysis of Cellular Uptake of Arsenic by ICP-MS
Cellular uptake was analysed for 6 h, 24 h, and 48 h by inductively coupled plasma-mass
spectroscopy (ICP-MS). For each analysis, the cells from the four different cell lines were seeded
into sixteen 75 cm2 flasks at 1 × 106 cells/flask, with two flasks for each treatment as duplicates.
Following a 24 h cell attachment, the cells were treated as follows: control (cells in complete media),
ATO lipo (5 µM ATO encapsulating liposomes), empty lipo (control liposomes without ATO), and ATO
(5 µM free ATO). After 6 h treatment, the cells were washed with PBS, trypsinised, and counted before
they were collected into Falcon tubes for further analysis. The cells were lysed by adding 2 mL of
nitric acid while vortexing and heating at a temperature of 60 ◦C for 5 min, and were topped up with 8
mL of deionised water. Arsenic concentration was analysed using ICP-MS (Thermo Fisher XSeries2,
Paisley, UK) and corrected to the cell number and total volume accordingly. The same procedure was
carried out for different samples after 24 and 48 h incubation.
4.7. Statistical Analysis
Statistical analysis described in the experimental sections was conducted using Minitab17
(Minitab Ltd., Coventry, UK). Statistical significance was determined by a two-sample t-test. p < 0.05
was considered to be significant. For flow cytometry, statistical analysis was carried out automatically
through the BD Calibur software (BD Biosciences, Oxford, UK) that was provided. The mean and
coefficient of variation (CV) were calculated accordingly.
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